Annotation Detail
Information
- Associated Genes
- BRCA2
- Associated Variants
-
BRCA2 LOSS-OF-FUNCTION
BRCA2 LOSS-OF-FUNCTION - Associated Disease
- pancreatic cancer
- Source Database
- CIViC Evidence
- Description
- In multicenter phase II study included individuals with a germline BRCA1/2 mutation and pancreatic cancer after gemcitabine treatment. Olaparib was administered at 400 mg twice per day. Tumor response rate was 21.7% (five of 23 patients).Stable disease more than 8 weeks was observed in 35% of patients.
- Variant Origin
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6076
- Gene URL
- https://civic.genome.wustl.edu/links/genes/7
- Variant URL
- https://civic.genome.wustl.edu/links/variants/132
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Pancreatic Cancer
- Evidence Direction
- Supports
- Drug
- Olaparib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25366685
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Olaparib | Sensitivity | true |